Merus N.V. and Biohaven Ltd. announced on January 13, 2025, a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs). This partnership leverages Merus’ Biclonics® technology platform with Biohaven’s next-generation ADC conjugation and payload platform technologies.
Under the agreement, Biohaven will be responsible for the preclinical ADC generation of three Merus bispecific antibodies. Merus will receive an upfront payment and a license fee upon ADC candidate nomination for the first program.
Upon mutual agreement to advance each program, the parties plan to share subsequent external development and commercialization costs. This collaboration expands Merus's pipeline into ADCs, a rapidly evolving area in oncology, and provides non-dilutive funding and expertise for new therapeutic avenues.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.